JPMORGAN CHASE & CO - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is and the CUSIP is 10806XAD4. A total of 45 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$1,589,812
-10.4%
2,095,000
-27.2%
0.00%
Q2 2023$1,774,385
+5.6%
2,879,000
+9.5%
0.00%
Q1 2023$1,681,000
+430925.6%
2,629,000
+183.0%
0.00%
Q4 2022$390
-99.9%
929,0000.0%0.00%
Q3 2022$387,000
+2.9%
929,0000.0%0.00%
Q2 2022$376,000
-36.6%
929,000
-24.4%
0.00%
Q1 2022$593,0001,229,0000.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
Diameter Capital Partners LP 52,257,000$39,745,1068.72%
Context Capital Management, LLC 32,083$24,0521.93%
BRAIDWELL LP 67,294,000$50,470,5001.60%
DeepCurrents Investment Group LLC 17,855,000$13,514,0560.59%
Aequim Alternative Investments LP 20,000,000$15,000,0000.57%
ADVENT CAPITAL MANAGEMENT /DE/ 29,488,000$22,116,0000.51%
SILVERBACK ASSET MANAGEMENT LLC 5,000,000$3,750,3750.51%
ARISTEIA CAPITAL, L.L.C. 25,280,000$18,960,0000.51%
SSI INVESTMENT MANAGEMENT LLC 8,217,000$6,121,6650.50%
ABSOLUTE INVESTMENT ADVISERS, LLC 4,604,000$3,430,5200.49%
View complete list of BRIDGEBIO PHARMA INC shareholders